[go: up one dir, main page]

AR064104A1 - Formas de dosificacion en microemulsion de valsartan, y metodos para elaborarlas - Google Patents

Formas de dosificacion en microemulsion de valsartan, y metodos para elaborarlas

Info

Publication number
AR064104A1
AR064104A1 ARP070105388A ARP070105388A AR064104A1 AR 064104 A1 AR064104 A1 AR 064104A1 AR P070105388 A ARP070105388 A AR P070105388A AR P070105388 A ARP070105388 A AR P070105388A AR 064104 A1 AR064104 A1 AR 064104A1
Authority
AR
Argentina
Prior art keywords
valsartan
microemulsion
prepare
methods
dosage forms
Prior art date
Application number
ARP070105388A
Other languages
English (en)
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of AR064104A1 publication Critical patent/AR064104A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Dispersion Chemistry (AREA)
  • Neurosurgery (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Biophysics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Hospice & Palliative Care (AREA)
  • Hematology (AREA)
  • Psychiatry (AREA)
  • Vascular Medicine (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medical Preparation Storing Or Oral Administration Devices (AREA)

Abstract

Un sistema de suministro de fármaco, por ejemplo un pre-concentrado en microemulsion, que forma espontáneamente una microemulsion cuando se pone en contacto con un medio acuoso. El sistema de suministro de fármaco contiene valsartan, un componente hidrofílico, un componente lipofílico, y un tensoactivo. Un componente hidrofílico particularmente util en el sistema es un polímero que es solido a temperatura ambiente, por ejemplo PEG solido. Reivindicacion 1: Una composicion farmacéutica, la cual comprende: (a) valsartan; y (b) un tensoactivo, un componente lipofílico, y un componente hidrofílico.
ARP070105388A 2006-12-05 2007-12-03 Formas de dosificacion en microemulsion de valsartan, y metodos para elaborarlas AR064104A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US86860406P 2006-12-05 2006-12-05

Publications (1)

Publication Number Publication Date
AR064104A1 true AR064104A1 (es) 2009-03-11

Family

ID=39365945

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP070105388A AR064104A1 (es) 2006-12-05 2007-12-03 Formas de dosificacion en microemulsion de valsartan, y metodos para elaborarlas

Country Status (15)

Country Link
US (1) US20100035949A1 (es)
EP (1) EP2111217A2 (es)
JP (1) JP2010511722A (es)
KR (1) KR20090086281A (es)
CN (1) CN101541306A (es)
AR (1) AR064104A1 (es)
AU (1) AU2007333355B2 (es)
BR (1) BRPI0720077A2 (es)
CA (1) CA2671495A1 (es)
CL (1) CL2007003484A1 (es)
MX (1) MX2009005947A (es)
PE (1) PE20081443A1 (es)
RU (1) RU2009125613A (es)
TW (1) TW200840596A (es)
WO (1) WO2008073731A2 (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102740841A (zh) * 2009-12-08 2012-10-17 株式会社一和 含有20-O-β-D-吡喃葡糖基-20(S)-原人参二醇的固体分散体
WO2014009434A1 (en) 2012-07-11 2014-01-16 Sandoz Ag Self-microemulsifying drug delivery system of abiraterone or abiraterone acetate
JP6882321B2 (ja) 2015-12-09 2021-06-02 フォスファージニクス リミテッド 医薬製剤
KR20190032265A (ko) * 2015-12-09 2019-03-27 포스파제닉스 리미티드 약제학적 제형
IL267006B2 (en) 2016-12-21 2024-11-01 Phosphagenics Ltd Process for phosphorylation of a complex alcohol with p4o10 at high temperatures, and products thereof
KR101920628B1 (ko) * 2017-04-12 2018-11-22 대원제약주식회사 안지오텐신 수용체 길항제를 포함하는 약제학적 조성물
CN111183991A (zh) * 2020-03-03 2020-05-22 安徽金敦福农业科技有限公司 一种含有百里香酚的农药组合物

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6248363B1 (en) * 1999-11-23 2001-06-19 Lipocine, Inc. Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
US20020102301A1 (en) * 2000-01-13 2002-08-01 Joseph Schwarz Pharmaceutical solid self-emulsifying composition for sustained delivery of biologically active compounds and the process for preparation thereof
US20020132839A1 (en) * 2000-06-22 2002-09-19 Ganter Sabina Maria Tablet formulations comprising valsartan
WO2006050123A1 (en) * 2004-10-29 2006-05-11 Novartis Ag Spontaneously dispersible pharmaceutical compositions
MX2007012947A (es) * 2005-04-18 2008-04-09 Rubicon Res Pvt Ltd Composiciones biomejoradas.

Also Published As

Publication number Publication date
AU2007333355A1 (en) 2008-06-19
CA2671495A1 (en) 2008-06-19
JP2010511722A (ja) 2010-04-15
WO2008073731A2 (en) 2008-06-19
BRPI0720077A2 (pt) 2013-12-24
TW200840596A (en) 2008-10-16
CL2007003484A1 (es) 2008-07-11
PE20081443A1 (es) 2008-12-23
WO2008073731A3 (en) 2009-03-19
CN101541306A (zh) 2009-09-23
MX2009005947A (es) 2009-06-17
AU2007333355B2 (en) 2011-10-20
US20100035949A1 (en) 2010-02-11
RU2009125613A (ru) 2011-01-20
EP2111217A2 (en) 2009-10-28
KR20090086281A (ko) 2009-08-11

Similar Documents

Publication Publication Date Title
AR064104A1 (es) Formas de dosificacion en microemulsion de valsartan, y metodos para elaborarlas
CL2009002073A1 (es) Composicion farmaceutica solida para la liberacion controlada de un agente activo activo en el tracto gastrointestinal que comprende al menos un agente acido con solubilidad de menos de 0,3 mg/ml en solucion acuosa a un ph alrededor del pka del agente acido, un polimero hidrofilo, un alcanizador; uso en trastornos cardiovasculares.
CL2007002649A1 (es) Composicion farmaceutica que comprende 2-[6-(3-amino-piperidin-1-il)-3-metil-2,4-dioxo-3,4-dihidro-2h-pirimidin-1-ilmetil]-4-fluoro-benzonitrilo; y uso para el tratamiento de la diabetes.
BRPI0714399B8 (pt) composição farmacêutica líquida oral
CY1120377T1 (el) Στερεη φαρμακευτικη δοσολογικη φαρμακοτεχνικη μορφη που περιεχει λοπιναβιρη
CL2009001080A1 (es) Procedimiento para encapsular agentes biologicamente activos en un vehiculo en forma de particulas, que comprende solubilizar en un agente de apareamiento de ion hidrofobo y un disolvente, disolver, formar la emulsion y obtener el vehiculo; vehiculo en forma de particulas; y composicion farmaceutica que comprende el vehiculo.
CL2010000188A1 (es) Metodo para el tratamiento de una infeccion en un sujeto que comprende la administracion de 9-[(2,2-dimetil-propilamino)-metil]-minociclina o de una sal de la misma; composicion farmaceutica que comprende dicho compuesto; y su uso.
WO2008128775A3 (en) Stabilised pharmaceutical composition containing pregabaline
CL2007002594A1 (es) Compuestos derivados de piridin-3-il, agentes inmunomoduladores; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto en el tratamiento de enfermedades asociadas con un sistema inmunologico activado. .
CL2012002522A1 (es) Composición farmacéutica que comprende un compuesto inhibidor de dpp iv con un grupo amino o una sal del mismo , un primer diluyente , un segundo diluyente ,un aglutinante , un disgregante y un lubricante, útil en el tratamiento de diabetes mellitus.
WO2007146227A3 (en) Flow-induced delivery from a drug mass
CR11167A (es) Uso de homo y copolimeros para la estabilizacion de formulaciones de principios activos
AR060016A1 (es) Sistema de liberacion de plaguicida
WO2009032481A3 (en) Stable emulsion formulation hindering interaction across the water-oil interface
BRPI0922435A2 (pt) "composto de tiazolopiridina moduladores de sirtuina, composição farmacêutica compreendendo o mesmo e seu uso."
EP2004172A4 (en) ACTIVE INK PROCESSING, STRUCTURES AND COMPOSITIONS FOR NASOLACRIMAL SYSTEM
MX2009011247A (es) Nanoparticulas que comprenden una ciclodextrina y una molecula biologicamente activa y sus aplicaciones.
AR053464A1 (es) Un sistema de suministro para componenetes activos y un material que tiene hidrofobicidad preseleccionada comoparte de una composicion comestible
BR112015021002A2 (pt) forma de dosagem sólida restringente de abuso para liberação imediata com entalhe funcional
WO2008067164A3 (en) Solid pharmaceutical dosage formulations
GT200800115A (es) Metodos para tratar infecciones del tracto gastrointestinal con tigeciclina
GT201000102A (es) Producto de dispersión sólida de drogas basadas en n-aril urea
WO2008081829A1 (ja) 難水溶性薬物の溶解性維持用アミノアルキルメタアクリレートコポリマーｅ
BR112012006056A2 (pt) forma de dosagem
WO2009016069A3 (en) Stable liquid pharmaceutical composition based on trazodone

Legal Events

Date Code Title Description
FB Suspension of granting procedure